Q-omics provides the consensus-scored NPM1P46 profile across patient tissues and cancer cell-line models. NPM1P46 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NPM1P46 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NPM1P46 RNA expression shows 14,795 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where NPM1P46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P46 survival associations across molecular data types. NPM1P46 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P46 RNA expression–survival associations across cancer types. High NPM1P46 expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in THCA, SKCM and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NPM1P46 RNA expression.
This table summarizes NPM1P46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P46 shows higher tumor expression in KIRC, LIHC, LUAD, COAD, KIRP and LUSC. The KIRC box plot shows higher NPM1P46 RNA expression in tumor versus normal tissue (log2 FC = +0.184, t-test p < 0.001).
This table shows molecular features associated with NPM1P46 in patient tissues and cancer cell lines. In patient samples, NPM1P46 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
